{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:16:05Z","timestamp":1783199765423,"version":"3.54.6"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.diabres.2022.109837","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T13:16:56Z","timestamp":1647609416000},"page":"109837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"186","author":[{"given":"Stefan D.","family":"Anker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif-Erik","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Fitchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pernille Ofstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Vedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry K.","family":"Yaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2022.109837_b0005","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1183\/09031936.00012408","article-title":"Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD","volume":"32","author":"Mannino","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diabres.2022.109837_b0010","doi-asserted-by":"crossref","unstructured":"Ho T-W, Huang C-T, Ruan S-Y, Tsai Y-J, Lai F, Yu C-J. Diabetes mellitus in patients with chronic obstructive pulmonary disease\u2013The impact on mortality. PLoS One 2017;12:e0175794.","DOI":"10.1371\/journal.pone.0175794"},{"key":"10.1016\/j.diabres.2022.109837_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2337\/dc09-0880","article-title":"Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer","volume":"33","author":"Ehrlich","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2022.109837_b0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfn013","article-title":"Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"04","key":"10.1016\/j.diabres.2022.109837_b0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0035-1556063","article-title":"Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management","volume":"36","author":"Putcha","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.diabres.2022.109837_b0030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/COPD.S242009","article-title":"Management of the COPD patient with comorbidities: an experts recommendation document","volume":"15","author":"Recio Iglesias","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"22","key":"10.1016\/j.diabres.2022.109837_b0035","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.diabres.2022.109837_b0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2022.109837_b0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2022.109837_b0050","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.diabres.2022.109837_b0055","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.109837_b0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2022.109837_b0065","doi-asserted-by":"crossref","unstructured":"Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.","DOI":"10.1007\/978-1-4419-0300-6"},{"key":"10.1016\/j.diabres.2022.109837_b0070","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol 1972;34:187\u2013220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"10.1016\/j.diabres.2022.109837_b0075","unstructured":"Long JS. Regression models for categorical and limited dependent variables. Thousand Oaks, CA: Sage publications; 1997."},{"issue":"4","key":"10.1016\/j.diabres.2022.109837_b0080","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1378\/chest.128.4.2005","article-title":"Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001","volume":"128","author":"Holguin","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.diabres.2022.109837_b0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ehf2.12055","article-title":"Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges","volume":"2","author":"Lainscak","year":"2015","journal-title":"ESC Heart Fail"},{"issue":"36","key":"10.1016\/j.diabres.2022.109837_b0090","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.diabres.2022.109837_b0095","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.diabres.2022.109837_b0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa0808836","article-title":"Percent emphysema, airflow obstruction, and impaired left ventricular filling","volume":"362","author":"Barr","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.109837_b0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12020-018-1554-z","article-title":"Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance","volume":"61","author":"Machado","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.diabres.2022.109837_b0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1513\/pats.200407-037MS","article-title":"Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease","volume":"2","author":"Naeije","year":"2005","journal-title":"Proc Am Thorac Soc"},{"issue":"10","key":"10.1016\/j.diabres.2022.109837_b0115","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jchf.2019.05.009","article-title":"Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease","volume":"7","author":"Canepa","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.diabres.2022.109837_b0120","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejhf.2083","article-title":"Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF","volume":"23","author":"Dewan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabres.2022.109837_b0125","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020: https:\/\/goldcopd.org\/wp-content\/uploads\/2020\/03\/GOLD-2020-POCKET-GUIDE-ver1.0_FINAL-WMV.pdf [accessed September 21, 2021]."},{"issue":"1","key":"10.1016\/j.diabres.2022.109837_b0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1107-x","article-title":"Consequences of chronic kidney disease in chronic obstructive pulmonary disease","volume":"20","author":"Trudzinski","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.diabres.2022.109837_b0135","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/COPD.S119390","article-title":"Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy","volume":"12","author":"Fedeli","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.diabres.2022.109837_b0140","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-14-151","article-title":"Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease","volume":"14","author":"Hasegawa","year":"2014","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.diabres.2022.109837_b0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/COPD.S234942","article-title":"Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review","volume":"15","author":"Iheanacho","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.diabres.2022.109837_b0150","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2022.109837_b0155","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1016\/j.diabres.2022.109837_b0160","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2022.109837_b0165","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2022.109837_b0170","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.amjmed.2010.06.019","article-title":"Inhaled corticosteroids and the risks of diabetes onset and progression","volume":"123","author":"Suissa","year":"2010","journal-title":"Am J Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722006490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722006490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:09Z","timestamp":1759173789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722006490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":34,"alternative-id":["S0168822722006490"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109837","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109837"}}